Viking Therapeutics
VKTX
148 hedge funds and large institutions have $753M invested in Viking Therapeutics in 2018 Q3 according to their latest regulatory filings, with 54 funds opening new positions, 53 increasing their positions, 31 reducing their positions, and 21 closing their positions.
157% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 21
151% more capital invested
Capital invested by funds: $300M → $753M (+$453M)
71% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 31
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
28% more funds holding
Funds holding: 116 → 148 (+32)
7.55% more ownership
Funds ownership: 53.84% → 61.39% (+7.6%)
4% less call options, than puts
Call options by funds: $35.3M | Put options by funds: $37M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$86M |
| 2 |
State Street
Boston,
Massachusetts
|
+$63.3M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$13.7M |
| 4 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$10.2M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$9.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$42.4M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$35.6M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$13.9M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$7.12M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$4.46M |
VKTX Hedge Fund Activity: Q3 2018 in Review
148 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q3 2018, worth a combined $753M — up 151% from $300M a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new VKTX positions and 21 closed out — a net gain of 33 holders — while 53 added to existing stakes and 31 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $86M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $42.4M sold.
- 148 institutional investors held Viking Therapeutics (VKTX) as of Q3 2018, up from 116 in Q2 2018.
- Funds reported $753M of Viking Therapeutics stock for Q3 2018, up 151% quarter-over-quarter.
- 54 funds opened new Viking Therapeutics positions in Q3 2018 and 21 closed out, a net change of +33 holders.
- The largest Viking Therapeutics buyer in Q3 2018 was Fidelity Investments, an estimated $86M added.
- The largest Viking Therapeutics seller in Q3 2018 was Avoro Capital Advisors, an estimated $42.4M sold.
Based on aggregated 13F filings for Q3 2018.